Phase II clinical trials showed that single‐agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant‐CRC, which may attribute to tumor specificity and feedback mechanisms and may be conquered by combination strategies.305. This evidence concerns the gene BRAF and colorectal carcinoma.